Androgen deprivation is the therapy of choice in the majority of patients with metastatic prostate cancer.
However, a state of castration resistance ultimately occurs after hormone therapy, thus defining metastatic castration-resistant prostate cancer (mCRPC). mCRPC has historically been considered a relatively chemoresistant tumor. However, due to its ability to improve survival and the quality of life in comparison with mitoxantrone, docetaxel has been established as the standard chemotherapeutic agent for first-line therapy since 2004. Moreover, recent results have shown that the novel taxane cabazitaxel is able to prolong the overall survival of patients with mCRPC previously treated with docetaxel. Even though these taxanes display a favorable toxicity profile, their routine use in clinical practice requires knowledge about the most frequent and distinct adverse events that may result from their administration.
Written by:
Schutz FA, Buzaid AC, Sartor O. Are you the author?
Hospital Sao Jose - Beneficencia Portuguesa de Sao Paulo, Sao Paulo, Brazil; Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, United States.
Reference: Crit Rev Oncol Hematol. 2014 Feb 15. pii: S1040-8428(14)00036-5.
doi: 10.1016/j.critrevonc.2014.02.003
PubMed Abstract
PMID: 24613528
UroToday.com mCRPC Treatment Section
